Boehringer Ingelheim discontinues female desire drug, citing FDA complete response letter
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has decided to abandon development of its investigational compound flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, citing a recent negative review by an FDA advisory panel and a complete response letter it received in late August from the US FDA.